Multiple myeloma: a descriptive study of 217 Egyptian patients

El Husseiny, Noha; Kasem, Neemat; El Azeeim, Hamdy; Mattar, Mervat
January 2014
Annals of Hematology;Jan2014, Vol. 93 Issue 1, p141
Academic Journal
Multiple myeloma is a neoplasm of plasma cells that results in the overproduction of light and heavy chain monoclonal immunoglobulins. The incidence rate increases with age, particularly after 40 years, and is higher in men. To determine the clinical and laboratory characteristics and survival of diagnosed Egyptian multiple myeloma patients admitted to the Haemato-Oncology Department between 2000 and 2010. Records of all patients in whom multiple myeloma was diagnosed at the Kasr Al Aini Hospital between 2000 and 2010 were included in this retrospective study. The mean age of patients was 58.5 years (range, 27-80 years). Fifty-nine percent were males. The majority of patients (73 %) had an immunoglobulin G monoclonal band and 70 % were Kappa chain-positive. Mean overall survival was 37.5 months (range, 1-84 months). Survival analysis was statistically insignificant with respect to age, sex, International Staging System and type of treatment ( p > 0.05). Our records were largely comparable to those reported in Chinese studies but different from those noted in Western and Arabic countries.


Related Articles

  • CLINIC ROUNDUP.  // BioWorld Today;7/21/2008, Vol. 19 Issue 140, p4 

    This article reports that a Phase I/II study of elotuzumab, a humanized anti-CS1 monoclonal immunoglobulin G1 (IgG1) antibody administered intravenously in combination with Velcase for Injection for relapsed multiple myeloma, has been started by the Multiple Myeloma Research Consortium. The...

  • Immunotherapy in multiple myeloma: Id-specific strategies suggested by studies in animal models. Corthay, Alexandre; Lundin, Katrin U.; Munthe, Ludvig A.; Fr√łyland, Marianne; Gedde-Dahl, Tobias; Dembic, Zlatko; Bogen, Bjarne // Cancer Immunology, Immunotherapy;Sep2004, Vol. 53 Issue 9, p759 

    Multiple myeloma (MM) cells produce monoclonal immunoglobulin (Ig) which serves as a truly tumor-specific antigen. The tumor-specific antigenic determinants are localized in the variable (V)-regions of the monoclonal Ig and are called idiotopes (Id). We review here the evidence obtained in a...

  • Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma. van de Donk, N W C J; Kamps, S; Mutis, T; Lokhorst, H M // Leukemia (08876924);Feb2012, Vol. 26 Issue 2, p199 

    The introduction of autologous stem cell transplantation combined with the introduction of immunomodulatory drugs (IMiDs) and proteasome inhibitors has significantly improved survival of multiple myeloma patients. However, ultimately the majority of patients will develop refractory disease,...

  • New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Ocio, E M; Richardson, P G; Rajkumar, S V; Palumbo, A; Mateos, M V; Orlowski, R; Kumar, S; Usmani, S; Roodman, D; Niesvizky, R; Einsele, H; Anderson, K C; Dimopoulos, M A; Avet-Loiseau, H; Mellqvist, U-H; Turesson, I; Merlini, G; Schots, R; McCarthy, P; Bergsagel, L // Leukemia (08876924);Mar2014, Vol. 28 Issue 3, p525 

    Treatment in medical oncology is gradually shifting from the use of nonspecific chemotherapeutic agents toward an era of novel targeted therapy in which drugs and their combinations target specific aspects of the biology of tumor cells. Multiple myeloma (MM) has become one of the best examples...

  • Effect of Discharge Summary Availability During Post-discharge Visits on Hospital Readmission. van Walraven, Carl; Seth, Ratika; Austin, Peter C; Laupacis, Andreas // JGIM: Journal of General Internal Medicine;Mar2002, Vol. 17 Issue 3, p186 

    OBJECTIVE: To determine if the delivery of hospital discharge summaries to follow-up physicians decreases the risk of hospital readmission. SUBJECTS: Eight hundred eighty-eight patients discharged from a single hospital following treatment for an acute medical illness. SETTING: Teaching hospital...

  • Use of medical record linkage to study readmission rates. Henderson, J.; Goldacre, M.J.; Graveney, M.J.; Simmons, H.M. // BMJ: British Medical Journal (International Edition);9/16/89, Vol. 299 Issue 6701, p709 

    Focuses on the use of medical record linkage for the readmission rates in Great Britain. Reduction on the likelihood of readmission; Variation in quality of care; Lack of outcome indicators.

  • TRANSFER OF ACCOUNTABILITY: SBAR Transfer of Accountability Template for Admitted Patients.  // ED Nursing;Apr2009 Supplement, p1 

    The article presents a medical information sheet for Situation, Background, Assessment, Recommendation (SBAR) Transfer of Accountability Template for Admitted Patients.

  • Elotuzumab: a new monoclonal antibody for multiple myeloma therapy. Staderini, Michela; Nozzoli, Chiara // Drugs & Cell Therapies in Hematology;2016, Issue 1, p68 

    For decades, since its first description, multiple myeloma represented a hard challenge for clinicians due to the scarce results obtained with conventional chemotherapies. Autologous stem cells transplantation and novel drugs such as immunomodulating drugs (IMIDs) and proteasome inhibitors (PIs)...

  • Daratumumab improves the anti-myeloma effect of newly emerging multidrug therapies. Gopalakrishnan, Sathish; Tan, Daryl // Blood & Lymphatic Cancer: Targets & Therapy;2013, Vol. 3, p19 

    Although the clinical outcomes of patients with multiple myeloma has improved tremendously with the advent of bortezomib and immunomodulatory drugs like thalidomide and lenalidomide, the disease remains incurable and patients will eventually be resistant to these drugs. Novel non-cross-resistant...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics